ID

19988

Descrizione

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT00372385

collegamento

https://clinicaltrials.gov/show/NCT00372385

Keywords

versioni (2)
  1. 02/02/17 02/02/17 -
  2. 03/02/17 03/02/17 -
Caricato su

2 febbraio 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Chronic Hepatitis C NCT00372385

Inglese

Eligibility Chronic Hepatitis C NCT00372385

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
hepatitis c virus genotype 1 with detectable plasma hepatitis c virus rna
Descrizione

Hepatitis C virus genotype 1 | Hepatitis C RNA positive

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3532919
UMLS CUI [2]
C0855842
have been infected with hepatitis c virus for greater than (>) 6 months
Descrizione

Hepatitis C virus infection Disease length

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3844790
UMLS CUI [1,2]
C0872146
seronegative for hepatitis b surface antigen and human immunodeficiency virus 1 and 2
Descrizione

Hepatitis B Surface Antigens Seronegative | HIV-1 Seronegative | HIV-2 Seronegative

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0019168
UMLS CUI [1,2]
C0521144
UMLS CUI [2,1]
C0019704
UMLS CUI [2,2]
C0521144
UMLS CUI [3,1]
C0019707
UMLS CUI [3,2]
C0521144
must agree to use 2 methods of contraception, including 1 barrier method, during and for 24 weeks after the completion of the study (unless the subject is a female of documented non-child-bearing potential)
Descrizione

Childbearing Potential Contraceptive methods Quantity | Contraception, Barrier

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C1265611
UMLS CUI [2]
C0004764
female subjects must have a negative pregnancy test at all visits before the first dose.
Descrizione

Gender Pregnancy test negative

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0427780
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
received any approved or investigational drug or drug regimen for the treatment of hepatitis c.
Descrizione

Pharmaceutical Preparations Approved Hepatitis C | Investigational New Drugs Hepatitis C

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0205540
UMLS CUI [1,3]
C0019196
UMLS CUI [2,1]
C0013230
UMLS CUI [2,2]
C0019196
any medical contraindications to peg-ifn-alfa-2a or ribavirin therapy
Descrizione

Medical contraindication peginterferon alfa-2a | Medical contraindication Ribavirin

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0391001
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0035525
any other cause of significant liver disease in addition to hepatitis c; this may include but is not limited to, hepatitis b, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, wilson's disease, nonalcoholic steatohepatitis or primary biliary cirrhosis.
Descrizione

Liver disease Significant Cause | Hepatitis C | Hepatitis B | Drug-induced cirrhosis of liver | Liver Cirrhosis, Alcoholic | Hepatitis, Autoimmune | Hemochromatosis | Hepatolenticular Degeneration | Nonalcoholic Steatohepatitis | Primary biliary cirrhosis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0023895
UMLS CUI [1,2]
C0750502
UMLS CUI [1,3]
C0015127
UMLS CUI [2]
C0019196
UMLS CUI [3]
C0019163
UMLS CUI [4]
C1960179
UMLS CUI [5]
C0023891
UMLS CUI [6]
C0241910
UMLS CUI [7]
C0018995
UMLS CUI [8]
C0019202
UMLS CUI [9]
C3241937
UMLS CUI [10]
C0008312
diagnosed or suspected hepatocellular carcinoma.
Descrizione

Liver carcinoma | Liver carcinoma Suspected

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2239176
UMLS CUI [2,1]
C2239176
UMLS CUI [2,2]
C0332147
histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 2 years before study start.
Descrizione

Liver Cirrhosis Evidence Biopsy of liver | Compensated cirrhosis Biopsy of liver

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0023890
UMLS CUI [1,2]
C0332120
UMLS CUI [1,3]
C0193388
UMLS CUI [2,1]
C1608426
UMLS CUI [2,2]
C0193388
alcohol/drug abuse or excessive use in the last 12 months.
Descrizione

Alcohol abuse | Alcohol intake above recommended sensible limits

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0085762
UMLS CUI [2]
C0560219
participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study).
Descrizione

Study Subject Participation Status | Investigational New Drugs | Drug study Quantity Participation

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
UMLS CUI [3,1]
C0013175
UMLS CUI [3,2]
C1265611
UMLS CUI [3,3]
C0679823
Ritorna all'inizio della pagina

Similar models

Eligibility Chronic Hepatitis C NCT00372385

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Hepatitis C virus genotype 1 | Hepatitis C RNA positive
Item
hepatitis c virus genotype 1 with detectable plasma hepatitis c virus rna
boolean
C3532919 (UMLS CUI [1])
C0855842 (UMLS CUI [2])
Hepatitis C virus infection Disease length
Item
have been infected with hepatitis c virus for greater than (>) 6 months
boolean
C3844790 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Hepatitis B Surface Antigens Seronegative | HIV-1 Seronegative | HIV-2 Seronegative
Item
seronegative for hepatitis b surface antigen and human immunodeficiency virus 1 and 2
boolean
C0019168 (UMLS CUI [1,1])
C0521144 (UMLS CUI [1,2])
C0019704 (UMLS CUI [2,1])
C0521144 (UMLS CUI [2,2])
C0019707 (UMLS CUI [3,1])
C0521144 (UMLS CUI [3,2])
Childbearing Potential Contraceptive methods Quantity | Contraception, Barrier
Item
must agree to use 2 methods of contraception, including 1 barrier method, during and for 24 weeks after the completion of the study (unless the subject is a female of documented non-child-bearing potential)
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0004764 (UMLS CUI [2])
Gender Pregnancy test negative
Item
female subjects must have a negative pregnancy test at all visits before the first dose.
boolean
C0079399 (UMLS CUI [1,1])
C0427780 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Pharmaceutical Preparations Approved Hepatitis C | Investigational New Drugs Hepatitis C
Item
received any approved or investigational drug or drug regimen for the treatment of hepatitis c.
boolean
C0013227 (UMLS CUI [1,1])
C0205540 (UMLS CUI [1,2])
C0019196 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2,1])
C0019196 (UMLS CUI [2,2])
Medical contraindication peginterferon alfa-2a | Medical contraindication Ribavirin
Item
any medical contraindications to peg-ifn-alfa-2a or ribavirin therapy
boolean
C1301624 (UMLS CUI [1,1])
C0391001 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0035525 (UMLS CUI [2,2])
Liver disease Significant Cause | Hepatitis C | Hepatitis B | Drug-induced cirrhosis of liver | Liver Cirrhosis, Alcoholic | Hepatitis, Autoimmune | Hemochromatosis | Hepatolenticular Degeneration | Nonalcoholic Steatohepatitis | Primary biliary cirrhosis
Item
any other cause of significant liver disease in addition to hepatitis c; this may include but is not limited to, hepatitis b, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, wilson's disease, nonalcoholic steatohepatitis or primary biliary cirrhosis.
boolean
C0023895 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0015127 (UMLS CUI [1,3])
C0019196 (UMLS CUI [2])
C0019163 (UMLS CUI [3])
C1960179 (UMLS CUI [4])
C0023891 (UMLS CUI [5])
C0241910 (UMLS CUI [6])
C0018995 (UMLS CUI [7])
C0019202 (UMLS CUI [8])
C3241937 (UMLS CUI [9])
C0008312 (UMLS CUI [10])
Liver carcinoma | Liver carcinoma Suspected
Item
diagnosed or suspected hepatocellular carcinoma.
boolean
C2239176 (UMLS CUI [1])
C2239176 (UMLS CUI [2,1])
C0332147 (UMLS CUI [2,2])
Liver Cirrhosis Evidence Biopsy of liver | Compensated cirrhosis Biopsy of liver
Item
histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 2 years before study start.
boolean
C0023890 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0193388 (UMLS CUI [1,3])
C1608426 (UMLS CUI [2,1])
C0193388 (UMLS CUI [2,2])
Alcohol abuse | Alcohol intake above recommended sensible limits
Item
alcohol/drug abuse or excessive use in the last 12 months.
boolean
C0085762 (UMLS CUI [1])
C0560219 (UMLS CUI [2])
Study Subject Participation Status | Investigational New Drugs | Drug study Quantity Participation
Item
participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study).
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0013175 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0679823 (UMLS CUI [3,3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial